From the publishers of JADPRO

MPN Resource Center


Atrial fibrillation and peripheral arterial disease define MPN patients with very high risk of thrombosis

Last Updated: Thursday, June 29, 2023

Data from a large cohort of MPN patients suggest that atrial fibrillation (AF) and peripheral arterial disease (PAD) are criteria for high-risk of thrombosis, hemorrhage, and death. Postdiagnosis thrombotic events were observed in 31.3% of patients who experienced AF (p = 0.002, OR = 1.80 [1.23; 2.61]), 35.8% of those who experienced PAD (p = 0.002, OR = 2.21 [1.31; 3.67]), and 62.1% of those who experienced both AF and PAD (p < 0.0001, OR = 6.47 [2.83; 15.46]) compared with 20.1% of the no-AF/no-PAD cohort. Postdiagnosis hemorrhagic events were also identified in 17.9%, 16%, 24.1%, and 10.1% of the AF, PAD, AF and PAD, and no-AF or PAD cohorts, respectively (p = 0.003).

Thrombosis Research
News & Literature Highlights

British Journal of Haematology

‘MPN Genomic Calculator’: real‐life use in a young population with essential thrombocythaemia


Significant association of cutaneous adverse events with hydroxyurea: results from a prospective non-interventional study in BCR-ABL1-negative myeloproliferative neoplasms (MPN) - on behalf of the German Study Group-MPN

Thrombosis Research

Patient outcomes in myeloproliferative neoplasm-related thrombosis: Insights from the National Inpatient Sample

British Journal of Haemtology

Real‐world non‐interventional long‐term post‐authorisation safety study of ruxolitinib in myelofibrosis

Cancer Medicine

Depressive symptoms and myeloproliferative neoplasms: Understanding the confounding factor in a complex condition

Expert Review of Hematology

Developing strategies to reduce the duration of therapy for patients with myeloproliferative neoplasms

European Society for Medical Oncology (ESMO) Congress 2021 Abstract

Final results of a phase II study of tipifarnib in chronic myelomonocytic leukemia (CMML) and other myelodysplastic/myeloproliferative neoplasms (MDS/MPN)

European Society for Medical Oncology (ESMO) Congress 2021 Abstract

Treatment outcomes and antibody immunity to SARS-CoV-2 in patients with hematological malignancies

Annals of Hematology

Evaluation of the need for cytoreduction and its potential carcinogenicity in children and young adults with myeloproliferative neoplasms

Clinical Lymphoma Myeloma and Leukemia

Mortality and causes of death of patients with polycythemia vera: analysis of the REVEAL prospective, observational study